{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:09:08Z","timestamp":1772168948679,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.157075.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000}},{"DOI":"10.12688\/f1000research.157075.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000}}],"reference-count":30,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Background: Antiviral therapy is not routinely recommended for chronic hepatitis B virus (HBV) infection in patients with elevated serum HBV DNA levels (&gt;2000 IU\/mL), normal alanine aminotransferase (ALT) levels, and no significant liver fibrosis, referred to as the \u201cindeterminate phase.\u201d This study aimed to identify factors associated with liver fibrosis progression in chronic HBV patients within this phase. Since the study\u2019s design, hepatitis B treatment guidelines have undergone significant evolution. New WHO recommendations published in 2024 advocate for expanded treatment criteria, making terms like \u201cIndeterminate phase\u201d obsolete. Methods This retrospective longitudinal cohort study was conducted at Farhat Hached University Hospital in Sousse, Tunisia, from January 2008 to January 2022. We included HBsAg-positive patients who were untreated, had a viral load &gt;2,000 IU\/mL for at least six months, normal ALT (&lt;40 IU\/L), and a fibrosis score of F0 and\/or F1 (determined by liver biopsy or FibroScan). Univariate and logistic regression analyses were performed to identify factors associated with liver fibrosis progression. Results A total of 97 patients were included, with a median age of 32.9 \u00b1 9.1 years and a female predominance (M\/F ratio = 0.64). Fibrosis progression occurred in 16 patients (16.5%), with a mean delay of 70.9 \u00b1 41.1 months. Univariate analysis showed significant associations between fibrosis progression and comorbidities (p = 0.001), high initial viral load (p = 0.004), elevated liver enzymes (p = 0.001), and increased viral load during follow-up (p = 0.002). Multivariate analysis identified comorbidities (p&lt;0.001) and changes in ALT levels (p&lt;0.001) as independent predictors of fibrosis progression. Conclusion Comorbidities and changes in ALT levels during follow-up were associated with fibrosis progression in the indeterminate phase of chronic HBV infection. Our findings support recent changes in international guidelines, including those from the WHO in 2024, which expand therapeutic indications for individuals living with hepatitis B.<\/ns3:p>","DOI":"10.12688\/f1000research.157075.3","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:15:08Z","timestamp":1756376108000},"page":"11","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated with Progressive Liver Disease in Untreated HBV Patients in Tunisia"],"prefix":"10.12688","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-5314","authenticated-orcid":false,"given":"Sana","family":"Rouis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-6674","authenticated-orcid":false,"given":"soumaya","family":"mrabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6348-150X","authenticated-orcid":false,"given":"Mohamed","family":"Ferjaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedia","family":"Ben Lasfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihene","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syrine","family":"Boujamline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rym","family":"Ayari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1633-6894","authenticated-orcid":false,"given":"Manel","family":"Ben Selma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariem","family":"Ben Ticha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foued","family":"Bellazreg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-8845","authenticated-orcid":false,"given":"Elhem","family":"Ben Jezia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Letaief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissem","family":"Hachfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","first-page":"24-30","DOI":"10.4254\/wjh.v3.i1.24","article-title":"First multicenter study of risk factors for hepatocellular carcinoma development in North Africa.","volume":"3","author":"O Bahri","year":"2011","journal-title":"World J. Hepatol."},{"key":"ref4","article-title":"Actualisation des recommandations tunisiennes.","year":"2019"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"370-398","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","author":"P Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1803-1812.e5","DOI":"10.1016\/j.cgh.2021.01.019","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients in the indeterminate phase.","volume":"20","author":"D Huang","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1-10","DOI":"10.1155\/2023\/7264601","article-title":"Clinical distribution characteristics and identification of significant liver inflammation in patients with chronic hepatitis B with indeterminate phase.","volume":"2023","author":"S Chen","year":"2023","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1025-1033","DOI":"10.1111\/jvh.13511","article-title":"Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone.","volume":"28","author":"K Yao","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1250-1257","DOI":"10.1111\/jgh.13667","article-title":"Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.","volume":"32","author":"J Li","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e00299","DOI":"10.14309\/ctg.0000000000000299","article-title":"Cost-effectiveness analysis of antiviral therapy for untreated, minimally active chronic hepatitis B to prevent liver disease progression.","volume":"12","author":"H Lee","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.14309\/ctg.0000000000000036","article-title":"Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders using antivirals.","volume":"10","author":"H Lee","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000140","article-title":"The natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase levels.","volume":"11","author":"H Lee","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref13","first-page":"635-646. e9","article-title":"Factors associated with HBsAg seroclearance rates in adults with chronic HBV infection: A systematic review and meta-analysis.","volume":"156","author":"Y Yeo","year":"2019","journal-title":"Gastroenterology."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3912-4018","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension.","volume":"45","author":"J McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11886-020-01331-z","article-title":"New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC\/AHA and 2019 ESC\/EAS Guidelines.","volume":"22","author":"V Raygor","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"965-985","DOI":"10.1007\/s00125-023-05894-8","article-title":"Evidence-based European recommendations for the dietary management of diabetes.","volume":"66","author":"A Aas","year":"2023","journal-title":"Diabetologia."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"237-264","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.","volume":"63","author":"Liver EAftSot.","year":"2015","journal-title":"J. Hepatol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2479-2494","DOI":"10.3748\/wjg.v29.i16.2479","article-title":"Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.","volume":"29","author":"S Jiang","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"193-201.e1","DOI":"10.1016\/j.cgh.2014.07.019","article-title":"Outcomes of patients with chronic hepatitis B who did not meet the criteria for antiviral treatment at presentation.","volume":"13","author":"S Yapali","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1317-1325","DOI":"10.1002\/hep.21178","article-title":"Development of a simple non-invasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"R Sterling","year":"2006","journal-title":"Hepatology."},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13010068","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.","volume":"13","author":"C Fernandez","year":"2024","journal-title":"Pathogens."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1747-1754.e1","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.","volume":"138","author":"J Chen","year":"2010","journal-title":"Gastroenterology."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/v13030368","article-title":"HBV integration studies in the clinic: Role in the natural history of infection.","volume":"13","author":"T Pollicino","year":"2021","journal-title":"Viruses."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1226755","DOI":"10.3389\/fcimb.2023.1226755","article-title":"The incidence of hepatocellular carcinoma and clearance of hepatitis B surface in CHB patients in the indeterminate phase: a systematic review and meta-analysis.","volume":"13","author":"M Liu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"215-226","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.","volume":"50","author":"G Choi","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"pbac030","DOI":"10.1093\/pcmedi\/pbac030","article-title":"Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA levels.","volume":"5","author":"J Zhou","year":"2022","journal-title":"Precis. Clin. Med."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"291-297","DOI":"10.1016\/j.jinf.2006.05.013","article-title":"Hepatitis B genotypes and precore\/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.","volume":"54","author":"K Ayed","year":"2007 Mar","journal-title":"J. Infect."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.28007054","author":"S Rouis","year":"2024","journal-title":"figshare."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.27172914.v1","author":"S Rouis","year":"2024","journal-title":"data sheet. figshare. Software."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.27172956.v1","author":"S Rouis","year":"2024","journal-title":"consent form. figshare. Software."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.27902625.v1","author":"S Rouis","year":"2024","journal-title":"Information letter. figshare. Software."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.29064221.v1","author":"S Rouis","year":"2024","journal-title":"STROBE statement. figshare. Journal contribution."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/14-11\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-11\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-11\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:55:10Z","timestamp":1757490910000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/14-11\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.12688\/f1000research.157075.3","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.157075.2","asserted-by":"subject"},{"id-type":"doi","id":"10.12688\/f1000research.157075.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.187074.r409443","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.187074.r432145","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.187074.r409443","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.187074.r432149","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/14-11\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.182035.r385856, Philippa C. Matthews, The Francis Crick Institute, London, 13 Jun 2025, version 2, 3 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/14-11\/v2#referee-response-385856","order":0,"name":"referee-response-385856","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.172481.r362298, Hela Gdoura, Gastro-enterology department, Hedi Chaker University Hospital, Sfax, 26 Apr 2025, version 1, 1 approved with reservations, 1 not approved","URL":"https:\/\/f1000research.com\/articles\/14-11\/v1#referee-response-362298","order":1,"name":"referee-response-362298","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Sana Rouis<\/b>; \n<i>Posted: 13 May 2025<\/i>; Dear Reviewer, thank you for taking the time to provide your valuable feedback and for your thoughtful comments on our work. We greatly appreciate your insights and have carefully considered your suggestions.  \n<b>Response to Reviewer 2:<\/b>  \n<b>Methods \u2013 Study Design:<\/b>&nbsp;We thank the reviewer for pointing out the error in the study design description. We have corrected it to &quot;retrospective longitudinal cohort study.&quot; \n<b>Results \u2013 Indeterminate Phase &amp; Comorbidities:<\/b>&nbsp;We agree with the reviewer's assessment of the clinical significance of our findings regarding the indeterminate phase and the importance of comorbidities. We have emphasized these points in the Discussion section. \n<b>Discussion \u2013 Initial Viral Load &amp; Causality:<\/b>&nbsp;We have clarified the interpretation of the initial viral load, acknowledging that it is a potential indicator but not an independent predictor. We have added a sentence to the Discussion emphasizing the need for prospective studies to explore the causal relationship between comorbidities and fibrosis.  I sincerely appreciate the time and care you\u2019ve taken to provide such a comprehensive and insightful review of my work. Your detailed feedback has been immensely helpful, and I\u2019m truly grateful for the effort you\u2019ve made to point out both the strengths and areas that need improvement. I\u2019ve thoughtfully considered each of your suggestions and have done my best to address them in this response. Your valuable insights have not only enhanced this project but will also serve as a guide for my future endeavors. I\u2019m deeply thankful for your expertise and constructive approach. Once again, thank you for your time and support\u2014it means a lot to me.","URL":"https:\/\/f1000research.com\/articles\/14-11\/v3#referee-comment-13894","order":2,"name":"referee-comment-13894","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.187074.r409443, Matrujyoti Pattnaik, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, 10 Sep 2025, version 3, indexed","URL":"https:\/\/f1000research.com\/articles\/14-11\/v3#referee-response-409443","order":3,"name":"referee-response-409443","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}